600521 Zhejiang Huahai Pharmaceutical

Huahai Pharma Gets Temporary FDA Approval for Brepiprazole Tablets

04:06 AM EDT, 03/24/2023 (MT Newswires) -- Zhejiang Huahai Pharmaceutical (SHA:600521) received temporary approval from the US Food and Drug Administration for its brepiprazole tablets after submittin

03-24 16:22

Huahai Pharmaceutical: Briprazole tablets have been temporarily approved by the US FDA

03-23 16:34

Huahai Pharmaceutical: The pharmaceutical product levaminapram sustained-release capsules obtained approval numbers from the US FDA.

03-22 16:32

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Zhejiang Huahai Pharmaceutical (SHSE:600521) has had a rough three months with its share price down 11%. However, the company's fundamentals look pretty decent, and long-term financials are usually

03-18 07:13

Mutual Pharmaceutical: The project jointly planned and constructed by Huahai is divided into 2 phases to build a total of 13 high-end steroidal APIs

03-08 13:46

Huahai Pharmaceutical (600521.SH): There will be no downward revision of the “Huahai Convertible Bonds” conversion price

Gelonghui, March 7, 丨 Huahai Pharmaceutical (600521.SH) announced that as of March 7, 2023, the company's stock price had been lower than 80% of the current conversion price for at least 15 trading days out of any 30 consecutive trading days, which touched on the “Huahai Transfer Bonds” conversion price downward revision clause. After deliberation and approval at the 11th interim meeting of the 8th board of directors of the company, the board of directors of the company decided not to exercise the right to revise the “Huahai Convertible Bonds” convertible price downward this time, and within the next 2 months (March 8, 2023 to May 7, 2023), if the convertible price of convertible bonds falls again

03-07 16:45

Huahai Pharma Gets Nod for Anti-Tumor Drug Trial

06:40 AM EST, 03/06/2023 (MT Newswires) -- Zhejiang Huahai Pharmaceutical (SHA:600521) obtained the approval of China's National Medical Products Administration for the clinical trial of HB0025 Inject

03-06 19:42

Huahai Pharmaceutical: Affiliated subsidiary obtains drug clinical trial license

03-05 15:51

The anti-tumor drug HB0025 injection from a subsidiary of Huahai Pharmaceutical (600521.SH) obtained approval for drug clinical trials

According to the Zhitong Finance App, Huahai Pharmaceutical (600521.SH) issued an announcement. Recently, the company's subsidiary Shanghai Huaotai Biopharmaceutical Co., Ltd. (hereinafter referred to as “Huaotai”) and Huabo Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Huabo Biology”) received the “Drug Clinical Trial Approval Notice” for the HB0025 injection approved and issued by the China Drug Administration (hereinafter referred to as “China Drug Administration”). According to reports, HB0025 (international generic drug name: Sotiburafusp alfa) is a type that uses a flexible connector to connect V

03-05 15:40

Huahai Pharmaceutical (600521.SH): “Huahai debt conversion” is expected to trigger a downward correction in the conversion price

Gelonhui, March 3, 丨 Huahai Pharmaceutical (600521.SH) announced that as of March 3, 2023, the closing price of the company's shares had been below 80% of the current conversion price for at least 10 trading days out of 30 consecutive trading days. “Huahai Convertible Bonds” is expected to trigger a downward revision of the conversion price. If the condition is triggered, the company will hold a board of directors on the day the condition is triggered to review and decide whether to revise the conversion price and promptly fulfill the obligation to disclose information.

03-03 17:45